Author

M. Itala-Remes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2

Frequent Co-Authors

U. Salmenniemi· 3 shared E. Loyttyniemi· 2 shared E. Makela· 2 shared J. Westermarck· 2 shared T. Varila· 2 shared A. Jerez· 1 shared A. Kreutzman· 1 shared A. M. Hurtado· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

U. Salmenniemi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Discovery of NOvel CIP2A VAriant (NOCIVA) and its clinical relevance in myeloid leukemias

E. Makela, K. Pavic, T. Varila, U. Salmenniemi, E. Loyttyniemi, S. Nagelli, V.-M. Kahari, R. E. Clark, V. K. Bachanaboyina, C. Lucas, M. Itala-Remes, J. Westermarck

The paper discovers a novel CIP2A splicing variant, NOCIVA, which is overexpressed in myeloid leukemias and correlates with poor clinical outcomes.

bioRxiv · Aug 24, 2020Cancer Biology

Somatic Mutations in Clonally Expanded T-lymphocytes in Patients with Chronic Graft-Versus-Host Disease

G. Park, S. Mustjoki, D. Kim, J. Huuhtanen, S. Lundgren, R. K. Khajuria, A. M. Hurtado, C. Munoz-Calleja, L. Cardenoso, V. Gomez-Garcia de Soria, T. H. Chen-Liang, S. Eldfors, P. Ellonen, S. Hannula, O. Bruck, , M. A. I. Keranen

This study identifies somatic mutations in clonally expanded T-cells in chronic GvHD patients, showing they drive persistent activation and resistance to mTOR inhibitors.

bioRxiv · Aug 31, 2019 · PreprintImmunology

ARPP19 promotes MYC expression and associates with patient relapse in acute myeloid leukemia

E. Makela, E. Loyttyniemi, U. Salmenniemi, O. Kauko, T. Varila, V. Kairisto, M. Itala-Remes, J. Westermarck

This study identifies ARPP19 as an oncogenic PP2A inhibitor in AML that predicts relapse independently of risk classification and is associated with disease activity.

bioRxiv · Jul 5, 2019Cancer Biology